Dabigatran Etexilate Mesylate
Brand Names: Pradaxa
Methodology & AI Transparency ⓘ
Dabigatran Etexilate Mesylate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Dabigatran Etexilate Mesylate (75 mg/1 Capsule and 150 mg/1 Capsule; NDC 0597-0355, 0597-0360) as a oral-route direct thrombin inhibitor formulation manufactured/labeled by Boehringer Ingelheim Pharmaceuticals Inc.
- 2 Real-world patient consensus: 74% patient "Worth It" rating across 7 anonymous logs for Dabigatran Etexilate Mesylate (RxNorm 1037179).
- 3 Typical cash cost range: 30-day cash pricing ranges from $18.93 on Cost Plus Drugs to $46.38 walk-in retail (NADAC $3.1576/unit).
- 4 Top reported side effects / signs: Most commonly reported Dabigatran Etexilate Mesylate tolerability events: nausea (7.5%), headache (6.6%), dizziness (4.8%).
Ask our AI Specialists anything about Dabigatran Etexilate Mesylate
Dabigatran Etexilate Mesylate Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Dabigatran Etexilate Mesylate (75 mg/1 Capsule and 150 mg/1 Capsule; NDC 0597-0355, 0597-0360) as a oral-route direct thrombin inhibitor formulation manufactured/labeled by Boehringer Ingelheim Pharmaceuticals Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Dabigatran Etexilate Mesylate exerts selective direct thrombin inhibitor pharmacodynamic activity across 75 mg/1 Capsule and 150 mg/1 Capsule (oral-route route, manufactured/labeled by Boehringer Ingelheim Pharmaceuticals Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0597-0355, 0597-0360).
Systemic exposure to Dabigatran Etexilate Mesylate reflects Estimated 59%–71% oral systemic absorption for Dabigatran Etexilate Mesylate absorption kinetics and phase i/ii hepatic conjugation of dabigatran etexilate mesylate coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 6–10 hours terminal plasma half-life for Dabigatran Etexilate Mesylate half-life window (peak plasma concentration (tmax) reached 1–3 hours post-dose for dabigatran etexilate mesylate response profile).
Dosing protocols (75 mg/1 Capsule or 150 mg/1 Capsule or 110 mg/1 Capsule or 75mg Bottle of Capsules or 110 mg Bottle of Capsules) balance efficacy (74.00% patient satisfaction across 7 logs) against nausea (7.5% of reports), headache (6.6% of reports), dizziness (4.8% of reports), with strict avoidance in known hypersensitivity to dabigatran etexilate mesylate or structurally related direct thrombin inhibitor compounds; concomitant contra-labeled cyp/transporter therapies during active dabigatran etexilate mesylate administration.
Avoid overlapping direct thrombin inhibitor prescriptions alongside Dabigatran Etexilate Mesylate to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Dabigatran Etexilate Mesylate dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Dabigatran Etexilate Mesylate or structurally related direct thrombin inhibitor compounds
- Concomitant contra-labeled CYP/transporter therapies during active Dabigatran Etexilate Mesylate administration
Logged Side-Effect Incidence (7 Reports)
Dabigatran Etexilate Mesylate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dabigatran Etexilate Mesylate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based Outcome model-based prediction facilitates estimating the average treatment effects of a drug in different target populations when treatment and outcome data are unreliable or unavailable. Clinical pharmacology and therapeutics • 2023-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37365904 ↗ |
Dabigatran Etexilate Mesylate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.1576/unit (~$94.73/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $18.93 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $46.38 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $21.77 / mo | View logs ↓ |
Dabigatran Etexilate Mesylate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dabigatran Etexilate Mesylate RxNorm Concept ID | 1037179 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1576 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $46.38 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $18.93 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 74.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dabigatran Etexilate Mesylate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Dabigatran Etexilate Mesylate integrating DailyMed SPL (2026-07-01), CMS NADAC ($3.1576/unit), and 7 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dabigatran Etexilate Mesylate community threads and patient logs by age, biological sex, dosage, and treatment duration.